Latest Acute Kidney Injury (AKI) News
Factors including low preoperative mean arterial BP tied to increases in eGFR, kidney injury.
Four single-nucleotide polymorphisms at two loci identified in discovery, replication populations.
Hyperphosphatemia was associated with more than double the risk of death from any cause.
The mortality rate among patients with negative fluid balance was just 7.4%, compared with 43.5% for patients with a positive fluid balance.
Study identifies 3 biomarkers that could detect increasing risk of worsening AKI in patients with acute cardiorenal syndrome.
This approach is associated with lower urine output during the first 7 days of therapy.
NSAIDs + diuretics with or without additional renin-angiotensin aldosterone agents demonstrated the strongest level of evidence.
In a meta-analysis, AKI was associated with an 86% increased risk of CV-related death and 38% increased risk of other major CV events.
The Food and Drug Administration (FDA) announced it is strengthening the current warning about the risk of acute kidney injury for drug products containing canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR).
Male gender, diabetes, and renal function decline at 90 days implicated as risk factors; patients rarely progress to end-stage renal disease.
Japanese study demonstrates a 2-fold increased risk of death from any cause.
High FiO2 and norepinephrine in AKI patients increases their risk of death within 24 hours of being placed on continuous renal replacement therapy.
Study demonstrates improved 90-day survival and greater likelihood of recovering renal function.
Patients were 40% less likely to die in 2011 compared with 2001, study finds.
Mortality no different for early versus delayed strategy for patients with severe acute kidney injury.
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)